AstraZeneca PLC ADR
AZN: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$89.00 | Kgfw | Cdqjfdjgk |
AstraZeneca Looks Well Positioned for Long-Term Growth Aided by Its Strong Pipeline
Business Strategy and Outlook
AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The replenishment of new drugs is offsetting the past patent losses on gastrointestinal drug Nexium and cholesterol reducer Crestor, and the company is well positioned for growth.